Search

Your search keyword '"Alex, Ansu Abu"' showing total 36 results
Start Over Author "Alex, Ansu Abu"
36 results on '"Alex, Ansu Abu"'

6. Arsenic trioxide resistance in acute promyelocytic leukemia: More to it than PML mutations

Author

Balasundaram, Nithya, primary, Ganesan, Saravanan, additional, Chendamarai, Ezhilarasi, additional, Palani, Hamenth Kumar, additional, Venkatraman, Arvind, additional, Alex, Ansu Abu, additional, David, Sachin, additional, Krishna, Sanjeev, additional, Korula, Anu, additional, Janet, Nancy Beryl, additional, Balasubramanian, Poonkuzhali, additional, and Mathews, Vikram, additional

Published
2020
Full Text
View/download PDF

7. A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide

Author

Kulkarni, Uday, primary, Ganesan, Saravanan, additional, Alex, Ansu Abu, additional, Palani, Hamenth, additional, David, Sachin, additional, Balasundaram, Nithya, additional, Venkatraman, Arvind, additional, Thenmozhi, Mani, additional, Jeyaseelan, Lakshmanan, additional, Korula, Anu, additional, Devasia, Anup, additional, Abraham, Aby, additional, Janet, Nancy Beryl, additional, Balasubramanian, Poonkuzhali, additional, George, Biju, additional, and Mathews, Vikram, additional

Published
2020
Full Text
View/download PDF

8. Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population

Author

David, Sachin, primary, Nair, Sukesh C., additional, Singh, G. Surender, additional, Alex, Ansu Abu, additional, Ganesan, Saravanan, additional, Palani, Hamenth Kumar, additional, Balasundaram, Nithya, additional, Lakshmi, Kavitha M., additional, Joshi, Aditi, additional, Kannan, S., additional, Korula, Anu, additional, Nambiatheyil Aboobacker, Fouzia, additional, Abraham, Aby, additional, George, Biju, additional, Apte, Shashikant Janardan, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2018
Full Text
View/download PDF

9. Arsenic Trioxide Enhances the NK Cell Cytotoxicity Against Acute Promyelocytic Leukemia While Simultaneously Inhibiting Its Bio-Genesis

Author

Alex, Ansu Abu, primary, Ganesan, Saravanan, additional, Palani, Hamenth Kumar, additional, Balasundaram, Nithya, additional, David, Sachin, additional, Lakshmi, Kavitha M., additional, Kulkarni, Uday P., additional, Nisham, P. N., additional, Korula, Anu, additional, Devasia, Anup J., additional, Janet, Nancy Beryl, additional, Abraham, Aby, additional, Srivastava, Alok, additional, George, Biju, additional, Padua, Rose Ann, additional, Chomienne, Christine, additional, Balasubramanian, Poonkuzhali, additional, and Mathews, Vikram, additional

Published
2018
Full Text
View/download PDF

13. Role of miRNA in Micro-Environment Mediated Drug Resistance in Acute Promyelocytic Leukemia to Arsenic Trioxide

Author

Ganesan, Saravanan, primary, Lakshmanan, Vairavan, additional, Palani, Hamenth Kumar, additional, Balasundaram, Nithya, additional, Alex, Ansu Abu, additional, David, Sachin, additional, Korula, Anu, additional, George, Biju, additional, Balasubramanian, Poonkuzhali, additional, Gowda, Harsha, additional, Vyas, Neha, additional, Palakodeti, Dasaradhi, additional, and Mathews, Vikram, additional

Published
2016
Full Text
View/download PDF

14. Osteoblast Differentiation of Stromal Cells Induced By Leukemic Cells

Author

Ganesan, Saravanan, primary, Palani, Hamenth Kumar, additional, Lakshmanan, Vairavan, additional, Balasundaram, Nithya, additional, Alex, Ansu Abu, additional, David, Sachin, additional, George, Biju, additional, Balasubramanian, Poonkuzhali, additional, Vyas, Neha, additional, Palakodeti, Dasaradhi, additional, and Mathews, Vikram, additional

Published
2016
Full Text
View/download PDF

16. Management of Relapsed Acute Promyelocytic Leukemia Post ATO Upfront Therapy: Open-Labeled Phase II Study Evaluating Role of Proteasome Inhibition

Author

Mathews, Vikram, primary, Korula, Anu, additional, Kulkarni, Uday, additional, Ganesan, Saravanan, additional, David, Sachin, additional, Alex, Ansu Abu, additional, PN, Nisham, additional, Abraham, Aby, additional, Srivastava, Alok, additional, Lakshmi, Kavitha M, additional, Balasubramanian, Poonkuzhali, additional, and George, Biju, additional

Published
2016
Full Text
View/download PDF

17. Prevalence of FVIII inhibitors in severe haemophilia A patients: Effect of treatment and genetic factors in an Indian population.

Author

David, Sachin, Alex, Ansu Abu, Ganesan, Saravanan, Palani, Hamenth Kumar, Balasundaram, Nithya, Lakshmi, Kavitha M., Korula, Anu, Nambiatheyil Aboobacker, Fouzia, Abraham, Aby, George, Biju, Srivastava, Alok, Mathews, Vikram, Nair, Sukesh C., Singh, G. Surender, Joshi, Aditi, Kannan, S., and Apte, Shashikant Janardan

Abstract

Introduction: Factor replacement therapy in treatment of haemophilia A is complicated by the production of neutralising antibodies known as inhibitors. The formation of inhibitors is multifactorial being associated with both genetic and environmental factors. Aim: To document the prevalence of inhibitors in severe haemophilia in the community where most patients receive only infrequent episodic replacement therapy and evaluate the factors which could be contributing to it. Methods: Community based camps were conducted in different parts of the country. Patients were assessed through a structured questionnaire and blood samples were obtained for laboratory evaluation of inhibitors and defined immunological parameters. Results: Inhibitors were present in 87/447 (19.5%) of the evaluated patients. High‐titre inhibitor (>5 Bethesda Units [BU]) was identified in 31 (35.6%) patients. HLA DRB1‐13‐positive cases (RR = 2.04; 95% CI 1.06‐3.911; P = 0.033) had an increased risk of inhibitor formation which was retained in the high‐titre subset. A decreased risk of inhibitor formation was noted with heterozygous IL4‐590 C/T allele (RR = 0.22; 95% CI 0.108‐0.442: P = 0.000). There were no significant correlations between any of the evaluated environmental factors and the development of inhibitors in this study. Conclusion: The overall prevalence of inhibitors in patients with severe haemophilia A is similar to that reported among patients receiving regular replacement therapy. The data from this study, limited by its retrospective and cross‐sectional study design, would suggest that genetic rather than environmental are more likely to impact the development of inhibitors. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

18. Prognostic Significance of Immunophenotypic Composition of B Cell Acute Lymphoblastic Leukemia at Diagnosis: A Novel Immunophenotype Based Risk Score

Author

Deshpande, Prashant, primary, Jain, Punit, additional, Alex, Ansu Abu, additional, Korula, Anu, additional, Lakshmi, Kavitha M, additional, N, Nisham P, additional, NA, Fouzia, additional, Abraham, Aby, additional, Srivastava, Alok, additional, Balasubramanian, Poonkuzhali, additional, George, Biju, additional, and Mathews, Vikram, additional

Published
2015
Full Text
View/download PDF

19. Adult Acute Lymphoblastic Leukemia: A Cost Effective Strategy and Limitations of Intensification of Therapy in India

Author

Jain, Punit, primary, Deshpande, Prashant, additional, Korula, Anu, additional, P N, Nisham, additional, Alex, Ansu Abu, additional, NA, Fouzia, additional, Lakshmi, Kavitha, additional, Abraham, Aby, additional, Balasubramanian, Poonkuzhali, additional, Srivastava, Alok, additional, George, Biju, additional, and Mathews, Vikram, additional

Published
2015
Full Text
View/download PDF

21. Comparison of Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide: Insight into Mechanisms of Resistance

Author

Chendamarai, Ezhilarasi, primary, Ganesan, Saravanan, additional, Alex, Ansu Abu, additional, Kamath, Vandana, additional, Nair, Sukesh C., additional, Nellickal, Arun Jose, additional, Janet, Nancy Beryl, additional, Srivastava, Vivi, additional, Lakshmi, Kavitha M., additional, Viswabandya, Auro, additional, Abraham, Aby, additional, Aiyaz, Mohammed, additional, Mullapudi, Nandita, additional, Mugasimangalam, Raja, additional, Padua, Rose Ann, additional, Chomienne, Christine, additional, Chandy, Mammen, additional, Srivastava, Alok, additional, George, Biju, additional, Balasubramanian, Poonkuzhali, additional, and Mathews, Vikram, additional

Published
2015
Full Text
View/download PDF

22. Proteasome Activity Is Dispensable for the Degradation of PML-RARα: Efficacy of Bortezomib Along with Arsenic Trioxide in the Treatment of Arsenic Sensitive and Resistant Acute Promyelocytic Leukemia

Author

Ganesan, Saravanan, primary, Alex, Ansu Abu, additional, Chendamarai, Ezhilarasi, additional, Balasundaram, Nithya, additional, Palani, Hamenth Kumar, additional, David, Sachin, additional, Rao, Jayandharan G, additional, Abraham, Aby, additional, Viswabandya, Auro, additional, George, Biju, additional, Srivastava, Alok, additional, Balasubramanian, Poonkuzhali, additional, Padua, Rose Ann, additional, Chomienne, Christine, additional, and Mathews, Vikram, additional

Published
2014
Full Text
View/download PDF

23. The Addition of Meloxicam to G-CSF Is Associated with Good Mobilization Rates, Faster Engraftment and Reduced Toxicity and Hospital Stay after Autologous Stem Cell Transplantation – a Phase II Study

Author

George, Biju, primary, Viswabandya, Auro, additional, Alex, Ansu Abu, additional, Lakshmi, Kavitha M, additional, Abraham, Aby, additional, Ganapule, Abhijeet, additional, N, Fouzia, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2014
Full Text
View/download PDF

25. NK Cell Mediated Cytotoxicity Against Malignant Promyelocytes Enhanced By Arsenic Trioxide: Potential Clinical Relevance

Author

Alex, Ansu Abu, primary, Kumar P, Hamenth, additional, Ganesan, Saravanan, additional, Balasundaram, Nithya, additional, Lakshmi, Kavitha M, additional, George, Biju, additional, Abraham, Aby, additional, Viswabandya, Auro, additional, Srivastava, Alok, additional, Padua, Rose Ann, additional, Chomienne, Christine, additional, Balasubramanian, Poonkuzhali, additional, and Mathews, Vikram, additional

Published
2013
Full Text
View/download PDF

26. Clinical, Cellular and Molecular Differences Between Newly Diagnosed and Relapsed Patients with Acute Promyelocytic Leukemia: Insights Into Mechanisms of Resistance

Author

Chendamarai, Ezhilarasi, primary, Alex, Ansu Abu, additional, Ganesan, Saravanan, additional, Kamath, Vandana, additional, Nair, Sukesh C, additional, Janet, Nancy Beryl, additional, Srivastava, Vivi M, additional, Lakshmi, Kavitha M, additional, Balasubramanian, Poonkuzhali, additional, Ahmed, Rayaz, additional, Abraham, Aby, additional, Viswabandya, Auro, additional, George, Biju, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2012
Full Text
View/download PDF

27. Myeloid Derived Suppressor Cells in Acute Leukemia and Its Association with Conventional Cytogenetic and Molecular Risk Factors

Author

Alex, Ansu Abu, primary, Tartour, Eric, additional, Gey, Alain, additional, Balasubramanian, Poonkuzhali, additional, Srivastava, Vivi, additional, Ahmed, Rayaz, additional, Abraham, Aby, additional, Viswabandya, Auro, additional, George, Biju, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2012
Full Text
View/download PDF

28. Community Based Evaluation of Prevalence of Inhibitors in Patients with Severe Hemophilia A in India and Their Correlation with Environmental and Genetic Factors

Author

David, Sachin, primary, Mathews, Vikram, additional, Apte, Shashikant, additional, Jayandharan, Giridhara R, additional, Nair, Sukesh C, additional, Daniel, Dolly, additional, Kumar, Suresh, additional, Alex, Ansu Abu, additional, Ganesan, Saravanan, additional, Subramanian, Kannan, additional, Ahmed, Rayaz, additional, Abraham, Aby, additional, Viswabandya, Auro, additional, George, Biju, additional, and Srivastava, Alok, additional

Published
2012
Full Text
View/download PDF

29. Mechanism of Synergy Between Bortezomib and Arsenic Trioxide in Acute Promyelocytic Leukemia and Clinical Efficacy in Relapsed Patients

Author

Ganesan, Saravanan, primary, Chendamarai, Ezhilarasi, additional, Alex, Ansu Abu, additional, David, Sachin, additional, Jayandharan, Giridhara R, additional, Balasubramanian, Poonkuzhali, additional, Ahmed, Rayaz, additional, Abraham, Aby, additional, Viswabandya, Auro, additional, George, Biju, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2012
Full Text
View/download PDF

30. Patterns of Immune Reconstitution in Patients with Acute Promyelocytic Leukemia Treated with Single Agent Arsenic Trioxide and Its Impact On Time to Molecular Remission

Author

Alex, Ansu Abu, primary, Ganesan, Saravanan, additional, Balasubramanian, Poonkuzhali, additional, Ahmed, Rayaz, additional, Abraham, Aby, additional, Viswabandya, Auro, additional, George, Biju, additional, Chendamarai, Ezhilarasi, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2012
Full Text
View/download PDF

31. Clinicopathological features of hepatosplenic T cell lymphoma: a single centre experience from India

Author

Patkar, Nikhil, primary, Nair, Sheila, additional, Alex, Ansu Abu, additional, Parihar, Mayur, additional, Manipadam, Marie Therese, additional, Arora, Neeraj, additional, Ahmed, Rayaz, additional, Abraham, Aby, additional, George, Biju, additional, Viswabandya, Auro, additional, Srivastava, Vivi, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2012
Full Text
View/download PDF

33. Rationale and Efficacy of Bortezomib in the Treatment of Acute Promyelocytic Leukemia in Combination with Arsenic Trioxide: In-Vitro and Phase I Data

Author

Ganesan, Saravanan, primary, Chendamarai, Ezhilarasi, additional, Rao, Jayandharan G, additional, Hareendran, Sangeetha, additional, Alex, Ansu Abu, additional, Ahmed, Rayaz, additional, Abraham, Aby, additional, Viswabandhya, Auro, additional, George, Biju, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2011
Full Text
View/download PDF

34. Role of Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia Treated with Arsenic Trioxide in Frontline Therapy

Author

Chendamarai, Ezhilarasi, primary, Balasubramanian, Poonkuzhali, additional, George, Biju, additional, Lakshmi, Kavitha M, additional, Viswabandhya, Auro, additional, Abraham, Aby, additional, Ahmed, Rayaz, additional, Alex, Ansu Abu, additional, Ganesan, Saravanan, additional, Chandy, Mammen, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2011
Full Text
View/download PDF

35. Evaluation of Mechanisms of Resistance to Arsenic Trioxide In Patients with Acute Promyelocytic Leukemia

Author

Chendamarai, Ezhilarasi, primary, Alex, Ansu Abu, additional, Ganesh, Saravanan, additional, Lakshmi, Kavitha M, additional, Jadhav, Sachin, additional, George, Biju, additional, Abraham, Aby, additional, Balasubramanian, Poonkuzhali, additional, Ramachandran, Shaji, additional, Srivastava, Alok, additional, and Mathews, Vikram, additional

Published
2010
Full Text
View/download PDF

36. Stromal-Cells Downregulate MiR-23a-5pLevels in Myeloid Leukemic Cells to Activate Protective-Autophagy Against Chemotherapeutic Agents

Author

Ganesan, Saravanan, Palani, Hamenth kumar, Lakshmanan, Vairavan, Balasundaram, Nithya, Alex, Ansu Abu, David, Sachin, Venkatraman, Arvind, Kulkarni, Uday Prakash, George, Biju, Srivastava, Alok, Balasubramanian, Poonkuzhali, Datta, Keshava K, Gowda, Harsha, Palakodeti, Dasaradhi, Vyas, Neha, and Mathews, Vikram

Abstract

Role of stromal micro-environment in drug resistance has been extensively reported for several cancers. We have demonstrated earlier that there is significant microenvironment mediated drug resistance (EMDR) to arsenic trioxide (ATO) in acute promyelocytic leukemia (APL) and that this was predominantly driven by up-regulation of the NF-kB pathway in the malignant cell (Ganesan S et al. Leukemia 2016). In our current study we have probed the molecular mechanism of EM-DR in further detail. Towards this we evaluated the potential role played by miRNA in EMDR to ATO in APL. Using NGS based small RNA sequencing we identified hsa-miR-23a-5pto be significantly downregulated (adjusted P value <0.01; figure 1a) in NB4 cells upon co-culture with HS-5 stromal cells. We noted that this miRNA is negatively regulated by NF-kB pathway and inversely correlated with NF-kB status in relapsed APL patients (n=8; matched samples). These results were consistent with our earlier reported observations that NF-kB pathway is dysregulated and enhances drug resistance to ATO. Further, we observed that low expression of miR-23a-5pobserved in the relapsed patient's samples showed a trend towards an increased association with subsequent second relapse.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results